DexCom Valuation
Is DXCM * undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of DXCM * when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: DXCM * (MX$2200) is trading above our estimate of fair value (MX$1411.62)
Significantly Below Fair Value: DXCM * is trading above our estimate of fair value.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for DXCM *?
Other financial metrics that can be useful for relative valuation.
What is DXCM *'s n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | US$50.37b |
Key Statistics | |
---|---|
Enterprise Value/Revenue | 13.2x |
Enterprise Value/EBITDA | 59x |
PEG Ratio | 4.3x |
Price to Earnings Ratio vs Peers
How does DXCM *'s PE Ratio compare to its peers?
Company | Forward PE | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 37.7x | ||
300760 Shenzhen Mindray Bio-Medical Electronics | 30.3x | 15.1% | CN¥368.4b |
EW Edwards Lifesciences | 36.3x | 9.8% | US$51.3b |
SHL Siemens Healthineers | 38.1x | 19.5% | €57.9b |
IDXX IDEXX Laboratories | 46.1x | 9.9% | US$39.5b |
DXCM * DexCom | 79.9x | 18.4% | Mex$50.4b |
Price-To-Earnings vs Peers: DXCM * is expensive based on its Price-To-Earnings Ratio (79.9x) compared to the peer average (37.6x).
Price to Earnings Ratio vs Industry
How does DXCM *'s PE Ratio compare vs other companies in the Global Medical Equipment Industry?
Price-To-Earnings vs Industry: DXCM * is expensive based on its Price-To-Earnings Ratio (79.9x) compared to the Global Medical Equipment industry average (28.5x).
Price to Earnings Ratio vs Fair Ratio
What is DXCM *'s PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PE Ratio | 79.9x |
Fair PE Ratio | n/a |
Price-To-Earnings vs Fair Ratio: Insufficient data to calculate DXCM *'s Price-To-Earnings Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
---|---|---|---|---|---|---|---|
Current | n/a | Mex$2,559.98 0% | 9.1% | Mex$2,889.00 | Mex$1,784.38 | n/a | 22 |
Apr ’25 | n/a | Mex$2,460.87 0% | 9.1% | Mex$2,826.11 | Mex$1,745.54 | n/a | 23 |
Mar ’25 | Mex$1,939.61 | Mex$2,496.31 +28.7% | 8.8% | Mex$2,898.84 | Mex$1,790.46 | n/a | 22 |
Feb ’25 | Mex$2,099.62 | Mex$2,464.21 +17.4% | 10.2% | Mex$2,944.20 | Mex$1,818.47 | n/a | 20 |
Jan ’25 | n/a | Mex$2,273.97 0% | 11.1% | Mex$2,742.20 | Mex$1,788.39 | n/a | 22 |
Dec ’24 | n/a | Mex$2,155.22 0% | 11.4% | Mex$2,664.53 | Mex$1,736.24 | n/a | 22 |
Nov ’24 | n/a | Mex$2,281.01 0% | 11.8% | Mex$2,806.51 | Mex$1,828.76 | n/a | 22 |
Oct ’24 | n/a | Mex$2,494.93 0% | 12.2% | Mex$2,808.83 | Mex$1,615.08 | n/a | 21 |
Sep ’24 | Mex$1,727.50 | Mex$2,492.38 +44.3% | 10.7% | Mex$2,976.28 | Mex$1,564.67 | n/a | 21 |
Aug ’24 | Mex$2,097.00 | Mex$2,462.86 +17.4% | 10.6% | Mex$2,930.27 | Mex$1,540.48 | n/a | 21 |
Jul ’24 | Mex$2,175.00 | Mex$2,388.26 +9.8% | 10.2% | Mex$2,603.85 | Mex$1,576.02 | n/a | 20 |
Jun ’24 | Mex$2,062.12 | Mex$2,436.91 +18.2% | 10.0% | Mex$2,643.74 | Mex$1,621.49 | n/a | 20 |
May ’24 | Mex$2,136.01 | Mex$2,479.52 +16.1% | 10.2% | Mex$2,696.99 | Mex$1,654.15 | Mex$2,200.00 | 20 |
Apr ’24 | n/a | Mex$2,367.45 0% | 10.4% | Mex$2,714.87 | Mex$1,665.12 | n/a | 20 |
Mar ’24 | n/a | Mex$2,384.42 0% | 10.2% | Mex$2,757.84 | Mex$1,691.48 | Mex$1,939.61 | 19 |
Feb ’24 | Mex$2,015.59 | Mex$2,385.59 +18.4% | 11.5% | Mex$2,817.63 | Mex$1,728.15 | Mex$2,099.62 | 18 |
Jan ’24 | Mex$2,123.63 | Mex$2,483.30 +16.9% | 11.9% | Mex$2,934.39 | Mex$1,799.76 | n/a | 17 |
Dec ’23 | Mex$2,248.00 | Mex$2,399.87 +6.8% | 9.4% | Mex$2,774.02 | Mex$1,822.92 | n/a | 17 |
Nov ’23 | Mex$2,395.00 | Mex$2,399.87 +0.2% | 9.4% | Mex$2,774.02 | Mex$1,822.92 | n/a | 17 |
Oct ’23 | Mex$1,676.69 | Mex$1,962.54 +17.0% | 9.2% | Mex$2,230.76 | Mex$1,613.32 | n/a | 15 |
Sep ’23 | n/a | Mex$1,970.39 0% | 9.4% | Mex$2,256.20 | Mex$1,631.71 | Mex$1,727.50 | 16 |
Aug ’23 | n/a | Mex$2,002.44 0% | 9.3% | Mex$2,283.02 | Mex$1,651.11 | Mex$2,097.00 | 17 |
Jul ’23 | Mex$1,464.09 | Mex$2,399.76 +63.9% | 16.9% | Mex$2,977.61 | Mex$1,607.91 | Mex$2,175.00 | 16 |
Jun ’23 | Mex$1,470.00 | Mex$2,614.00 +77.8% | 12.7% | Mex$2,975.43 | Mex$1,562.10 | Mex$2,062.12 | 17 |
May ’23 | n/a | Mex$2,745.54 0% | 13.2% | Mex$3,214.37 | Mex$1,607.19 | Mex$2,136.01 | 18 |
Analyst Forecast: Target price is less than 20% higher than the current share price.